

---

## CONTENTS

<b>1. INTRODUCTION</b>	<b>1-12</b>
1.1. Alzheimer's Disease	1
1.1.1. Causes and Pathophysiology	5
1.1.1.1. Cholinergic hypothesis	5
1.1.1.2. Amyloid hypothesis	7
1.1.1.3. Tau protein hypothesis	8
1.1.1.4. Oxidative stress	9
1.1.1.5. Metal ion hypothesis	10
<b>2. LITERATURE REVIEW</b>	<b>13-25</b>
2.1. FDA approved drugs for the treatment of AD	13
2.2. Reported MTDLs for treatment of AD	14
2.2.1. Indole based anti-AD agents	14
2.2.2. Carbazole based anti-AD agents	16
2.2.3. Stilbene based anti-AD agents	22
2.2.4. Tertiary amine fragment containing anti-AD agents	28
<b>3. AIMS AND OBJECTIVES</b>	<b>33-34</b>
<b>4. RESULTS AND DISCUSSION</b>	<b>35-188</b>
4.1. Triazinoindole based multifunctional anti-AD agents	35
4.1.1. 3-Substituted [1,2,4]triazino[5,6- <i>b</i> ]indole derivatives	35
4.1.1.1. Designing aspect of 3-substituted[1,2,4]triazino[5,6- <i>b</i> ] indole derivatives as anti-AD agents	35
4.1.1.2. Synthesis of the designed triazinoindole derivatives	38
4.1.1.2.1. Synthesis of <i>N</i> -substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-amine derivatives (71-80)	38
4.1.1.2.2. Synthesis of 5-substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-amine derivatives (117-126)	46
4.1.1.2.3. Synthesis of <i>N</i> -(aminoalkyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-amine derivatives (179-202)	55
4.1.1.3. Biological evaluation of the synthesized compounds	69
4.1.1.3.1. Inhibition studies on cholinesterase enzymes	69
4.1.1.3.2. Antioxidant activity [1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity]	74

4.1.1.3.3. Assessment of cytotoxicity and neuroprotection offered by the synthesized compounds	76
4.1.1.3.4. <i>In vitro</i> blood-brain barrier permeation assay	78
4.1.1.3.5. Assessment of cognitive improvement in animal model of AD	80
4.1.1.3.6. Acute toxicity study	84
4.1.1.4. Computational studies of the most promising compound	84
<b>4.1.2. 3- And 6-/7-/8-/9-disubstituted [1,2,4]triazino[5,6-<i>b</i>] indole derivatives</b>	<b>94</b>
4.1.2.1. Designing aspect of 3- and 6-/7-/8-/9-disubstituted [1,2,4]triazino [5,6- <i>b</i> ]indole derivatives	94
4.1.2.2. Synthesis of the C <sub>6</sub> -C <sub>9</sub> -substituted <i>N</i> -(aminoalkyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole derivatives (249-257, 261)	95
4.1.2.3. Biological evaluation of the synthesized compounds	105
4.1.2.3.1. Inhibition studies on cholinesterase enzymes	106
4.1.2.3.2. Antioxidant activity [1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging activity]	107
4.1.2.3.3. <i>In vitro</i> blood-brain barrier permeation assay	108
4.1.2.3.4. Assessment of cognitive improvement in animal model of AD	108
4.1.2.4. Computational studies of the most promising compound	111
<b>4.2. Carbazole based multifunctional anti-AD agents</b>	<b>116</b>
<b>4.2.1. Carbazole based stilbene derivatives</b>	<b>116</b>
4.2.1.1. Designing of novel carbazole based stilbene derivatives as anti-AD agents	116
4.2.1.2. Synthesis of the designed carbazole based stilbene derivatives	119
4.2.1.2.1. Synthesis of carbazole based stilbene derivative (Series-1)	119
4.2.1.2.2. Synthesis of carbazole based stilbene derivative (Series-2)	131
4.2.1.3. Biological evaluation of the synthesized compounds	148

4.2.1.3.1. <i>In vitro</i> cholinesterase inhibition studies	148
4.2.1.3.2. Self-mediated A $\beta$ <sub>1-42</sub> aggregation inhibition study	152
4.2.1.3.3. Antioxidant Activity (DPPH radical scavenging activity)	155
4.2.1.3.4. Metal Chelation study	155
4.2.1.4. Computational studies of the most promising compound	157
<b>4.2.2. Carbazole based azahelicene derivatives</b>	<b>162</b>
4.2.2.1. Designing of carbazole based azahelicene derivatives as anti-AD agents	163
4.2.2.2. Synthesis and characterization of the envisaged azahelicene	164
4.2.2.3. Biological evaluation of the synthesized compounds (316-329) as anti-AD agents	178
4.2.2.3.1. <i>In vitro</i> cholinesterase inhibition studies	179
4.2.2.3.2. Self-mediated A $\beta$ <sub>1-42</sub> aggregation inhibition study	181
4.2.2.3.3. Metal Chelation study	182
4.2.2.4. Computational studies of the most promising compound (329)	183
<b>5. EXPERIMENTAL</b>	<b>189-294</b>
<b>5.1. Chemical Studies</b>	<b>189</b>
5.1.1. Triazinoindole based multifunctional anti-AD agents	190
5.1.1.1. 5 <i>H</i> -[1,2,4]Triazino[5,6- <i>b</i> ]indole-3-thiol (68)	190
5.1.1.2. 3-(Methylthio)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole (69)	190
5.1.1.3. 3-(Methylsulfonyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole (70)	191
5.1.1.4. Synthesis of <i>N</i> -Substituted 5 <i>H</i> -[1,2,4]Triazino[5,6- <i>b</i> ]indol-3-amine derivatives (71-80)	191
5.1.1.5. Synthesis of <i>N</i> -substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indol-3-amine derivatives (117-126)	197
5.1.1.5.1. Synthesis of <i>N</i> -substituted isatins (81-89)	197
5.1.1.5.2. Synthesis of 5-substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indol-3-thiol derivatives (90-98)	197
5.1.1.5.3. Synthesis of 5-substituted 3-(methylthio)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole derivatives (99-107)	198

<b>5.1.1.5.4.</b> Synthesis of 5-substituted 3-(methylsulfonyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indole derivatives (108-116)	201
<b>5.1.1.5.5.</b> Synthesis of 5-substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-amine derivatives (117-126)	201
<b>5.1.1.6.</b> Synthesis of <i>N</i> -(aminoalkyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-amine derivatives (179-202)	206
<b>5.1.1.6.1.</b> Synthesis of <i>N</i> -(bromoalkyl)phthalimides (128-130)	206
<b>5.1.1.6.2.</b> Synthesis of <i>N,N</i> -(disubstituted-amino)alkylamines (155-178)	207
<b>5.1.1.6.3.</b> Synthesis of desired <i>N</i> -(aminoalkyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indol-3-amine derivatives (179-202)	208
<b>5.1.1.7.</b> 3- And 6-/7-/8-/9-disubstituted [1,2,4]triazino[5,6- <i>b</i> ] indole derivatives	224
<b>5.1.1.7.1.</b> Synthesis of substituted isatins (212-221)	224
<b>5.1.1.7.2.</b> Synthesis of substituted 5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ] indol-3-thiol derivatives (222-230, 258)	228
<b>5.1.1.7.3.</b> Synthesis of substituted 3-(methylthio)-5 <i>H</i> -[1,2,4] triazino[5,6- <i>b</i> ]indole derivatives (231-239, 259)	231
<b>5.1.1.7.4.</b> Synthesis of substituted-3-(methylsulfonyl)-5 <i>H</i> -[1,2,4] triazino[5,6- <i>b</i> ]indole derivatives (240-248, 260)	235
<b>5.1.1.7.5.</b> Synthesis of C <sub>6</sub> -C <sub>9</sub> -substituted <i>N</i> -(aminoalkyl)-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indol-3-amine derivatives (249-257, 261, 262)	235
<b>5.1.1.7.5k.</b> 8-Bromo- <i>N</i> -methyl-5 <i>H</i> -[1,2,4]triazino[5,6- <i>b</i> ]indol-3-amine (262)	242
<b>5.1.2.</b> Carbazole based multifunctional anti-AD agent	242
<b>5.1.2.1.</b> Carbazole based stilbene derivatives	242
<b>5.1.2.1.1.</b> Synthesis of carbazole based stilbene derivative (Series-1)	242
<b>5.1.2.1.1.1.</b> 9-Ethyl-9 <i>H</i> -carbazole (267)	242
<b>5.1.2.1.1.2.</b> 9-Ethyl-9 <i>H</i> -carbazole-3-carbaldehyde (268)	243
<b>5.1.2.1.1.3.</b> 9-Ethyl-6-nitro-9 <i>H</i> -carbazole-3-carbaldehyde (269)	243
<b>5.1.2.1.1.4.</b> ( <i>E</i> )-9-Ethyl-3-nitro-6-styryl-9 <i>H</i> -carbazole (270)	244
<b>5.1.2.1.1.5.</b> ( <i>E</i> )-9-Ethyl-6-styryl-9 <i>H</i> -carbazol-3-amine (271)	245

<b>5.1.2.1.1.6.</b> General method for the synthesis of ( <i>E</i> )- <i>N</i> -(9-ethyl-6-styryl-9 <i>H</i> -carbazol-3-yl)alkylamides (272-274)	246
<b>5.1.2.1.1.7.</b> General procedure for the synthesis of ( <i>E</i> )- <i>N</i> -(9-ethyl-6-styryl-9 <i>H</i> -carbazol-3-yl)aminoalkylamide (275-280)	247
<b>5.1.2.1.1.8.</b> General method E for the synthesis of ( <i>E</i> )-1-(9-ethyl-6-styryl-9 <i>H</i> -carbazol-3-yl)amino alkylurea (281-286)	251
<b>5.1.2.1.2.</b> Synthesis of carbazole based stilbene derivative (Series-2)	255
<b>5.1.2.1.2.1.</b> 2-(4-Nitrophenyl)acetic acid (287)	255
<b>5.1.2.1.2.2.</b> ( <i>E</i> )-9-Ethyl-3-(4-nitrostyryl)-9 <i>H</i> -carbazole (288)	255
<b>5.1.2.1.2.3.</b> ( <i>E</i> )-4-(2-(9-Ethyl-9 <i>H</i> -carbazol-3-yl)vinyl)aniline (289)	256
<b>5.1.2.1.2.4.</b> General method F for the synthesis of ( <i>E</i> )-chloro- <i>N</i> -(4-(2-(9-ethyl-9 <i>H</i> -carbazol-3-yl)vinyl)phenyl)alkylamide (290-292)	257
<b>5.1.2.1.2.5.</b> General method for the synthesis of ( <i>E</i> )- <i>N</i> -(4-(2-(9-ethyl-9 <i>H</i> -carbazol-3-yl)vinyl)phenyl)aminoalkylamide (293-298)	258
<b>5.1.2.1.2.6.</b> General method for synthesis of ( <i>E</i> )- <i>N</i> -(4-(2-(9-ethyl-9 <i>H</i> -carbazol-3-yl)vinyl)phenyl)aminoalkylurea (299-304)	263
<b>5.1.2.1.2.7.</b> General method for the synthesis of ( <i>E</i> )-1-(9-ethyl-6-styryl-9 <i>H</i> -carbazol-3-yl)-3-(aminoalkyl)thiourea (305-307)	268
<b>5.1.2.2.</b> Carbazole based azahelicene derivatives (316-329)	271
<b>5.1.2.2.1.</b> (4-Bromobenzyl)triphenylphosphonium bromide (309)	271
<b>5.1.2.2.2.</b> 3-(4-Bromostyryl)-9-ethyl-9 <i>H</i> -carbazole (310)	271
<b>5.1.2.2.3.</b> 2-Bromo-9-ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ]carbazole (311)	272
<b>5.1.2.2.4.</b> 9-Ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ]carbazol-2-amine (312)	272
<b>5.1.2.2.5.</b> General method for the synthesis of <i>N</i> -(9-ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ] carbazol-2-yl)alkylamides (313-315)	273
<b>5.1.2.2.6.</b> General procedure for the synthesis of 1-(9-ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ]carbazol-2-yl)aminoalkylamide (316-321)	275
<b>5.1.2.2.7.</b> General method E for the synthesis of 1-(9-ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ]carbazol-2-yl)aminoalkylurea (322-327)	279

---

5.1.2.2.8. General method for the synthesis of 1-(9-ethyl-9 <i>H</i> -naphtho[2,1- <i>c</i> ]carbazol-2-yl)aminopropylthiourea (328, 329)	283
<b>5.2. Biological studies</b>	<b>285</b>
5.2.1. Inhibition Studies on AChE and BuChE	285
5.2.2. Antioxidant Activity [1,1-Diphenyl-2-picrylhydrazyl (DPPH) Radical Scavenging Activity] Self-induced A $\beta$ <sub>1-42</sub> aggregation inhibition study	286
5.2.3. Self-induced A $\beta$ <sub>1-42</sub> aggregation inhibition study	286
5.2.4. Metal-chelating study	287
5.2.5. Cell Culture Studies	287
5.2.6. Determination of Cell Viability and Neuroprotection	287
5.2.7. <i>In vitro</i> blood-brain barrier permeation assay	288
5.2.8. Assessment of Cognitive Improvement in an Animal Model of AD	289
5.2.9. Acute toxicity study	292
<b>5.3. Computational Studies</b>	<b>292</b>
5.3.1. Docking Studies	292
5.3.2. Molecular Dynamics Simulations	293
5.3.3. <i>In Silico</i> Prediction of Physicochemical and Pharmacokinetics Parameters of the compounds	294
<b>6. CONCLUSION</b>	<b>295-297</b>
<b>REFERENCES</b>	<b>298-317</b>
<b>SUPPLEMENTARY MATERIAL</b>	<b>S1-S26</b>